Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endomatrix

Division of Becton Dickinson & Co.
www.endomatrix.com

Latest From Endomatrix

Exploramed: Incubators the Second Time Around

Ten years ago, when Josh Makower, MD, started an incubator, ExploraMed Inc., it was arguably the device industry's first. Makower proposed a different model for device company creation: to begin without a clear idea of the business, but, backed by some money and a vision of the clinical need, to search for the right technology to address that need. Now, a year after selling one of the incubator's start-ups, TransVascular, to Medtronic, Makower has resurrected ExploraMed, and he's just funded his first company. While the model remains largely the same, subtle differences between ExploraMed I and ExploraMed II highlight how much the medical device start-up world has changed over the past decade.
Medical Device Business Strategies

Beyond Bypass: Next Generation Coronary Revascularization

Traditional coronary artery bypass graft (CABG) surgery has been refined to be the most effective long-term treatment for occluded coronary arteries. Yet it remains a major surgical procedure that is traumatic for patients. Various minimally-invasive approaches to cardiac surgery have been developed but adoption rates are slow because these new procedures don't yet measure up to traditional CABG and because heart surgeons are slow adopters of new technology. Recent discoveries in coronary physiology have opened the door for new approaches to creating cardiac perfusion in a patient with occluded vessels. But this requires physicians to re-think what they were taught in medical school. One such approach, which involves direct vascularization from the ventricle, is being pursued by three companies: Percardia, HeartStent and Ventrica. Another company, TransVascular, is taking a broader approach by using the venous system to bypass arterial blockages. Approaches that require physicians to think differently about basic science, along with the tortuous clinical and regulatory path for new cardiac surgery devices and the cautious nature of cardiothoracic surgeons, present significant challenges to these start-up companies.
Medical Device Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Becton Dickinson & Co.
  • Senior Management
  • Daniel L Marks, CEO
  • Contact Info
  • Endomatrix
    Phone: (707) 256-3621
    433 Soscol Ave., Ste. A130
    Napa, CA 94559
    USA
UsernamePublicRestriction

Register